Riluzole topical - Biofrontera AG
Alternative Names: BF-37Latest Information Update: 02 Oct 2021
At a glance
- Originator Biofrontera AG
- Class Benzothiazoles; Neuroprotectants; Small molecules
- Mechanism of Action T lymphocyte inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Suspended Atopic dermatitis; Psoriasis
Most Recent Events
- 07 May 2007 Biofrontera initiates enrolment in a phase II trial for Atopic dermatitis in Germany
- 15 Mar 2007 Phase-II development is ongoing
- 08 Sep 2005 Biofrontera AG acquires topical riluzole from Switch Biotech AG